BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38142662)

  • 1. Artesunate in glioblastoma therapy: Case reports and review of clinical studies.
    Strik H; Efferth T; Kaina B
    Phytomedicine; 2024 Jan; 123():155274. PubMed ID: 38142662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
    Beltzig L; Christmann M; Kaina B
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
    Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
    J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation.
    Kim SH; Yoo H; Chang JH; Kim CY; Chung DS; Kim SH; Park SH; Lee YS; Yang SH
    J Korean Med Sci; 2018 Jun; 33(24):e167. PubMed ID: 29892208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
    Gilbert MR; Gonzalez J; Hunter K; Hess K; Giglio P; Chang E; Puduvalli V; Groves MD; Colman H; Conrad C; Levin V; Woo S; Mahajan A; de Groot J; Yung WK
    Neuro Oncol; 2010 Nov; 12(11):1167-72. PubMed ID: 20729242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.
    Combs SE; Gutwein S; Schulz-Ertner D; van Kampen M; Thilmann C; Edler L; Wannenmacher MM; Debus J
    Strahlenther Onkol; 2005 Jun; 181(6):372-7. PubMed ID: 15925979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.
    Stupp R; Hegi ME; Gorlia T; Erridge SC; Perry J; Hong YK; Aldape KD; Lhermitte B; Pietsch T; Grujicic D; Steinbach JP; Wick W; Tarnawski R; Nam DH; Hau P; Weyerbrock A; Taphoorn MJ; Shen CC; Rao N; Thurzo L; Herrlinger U; Gupta T; Kortmann RD; Adamska K; McBain C; Brandes AA; Tonn JC; Schnell O; Wiegel T; Kim CY; Nabors LB; Reardon DA; van den Bent MJ; Hicking C; Markivskyy A; Picard M; Weller M; ; ;
    Lancet Oncol; 2014 Sep; 15(10):1100-8. PubMed ID: 25163906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas.
    Kaina B; Christmann M
    DNA Repair (Amst); 2019 Jun; 78():128-141. PubMed ID: 31039537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.
    Patil VM; Bhelekar A; Menon N; Bhattacharjee A; Simha V; Abhinav R; Abhyankar A; Sridhar E; Mahajan A; Puranik AD; Purandare N; Janu A; Ahuja A; Krishnatry R; Gupta T; Jalali R
    Cancer Med; 2020 Jul; 9(13):4676-4685. PubMed ID: 32400117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
    Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
    J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.
    Taal W; Segers-van Rijn JM; Kros JM; van Heuvel I; van der Rijt CC; Bromberg JE; Sillevis Smitt PA; van den Bent MJ
    J Neurooncol; 2012 May; 108(1):195-200. PubMed ID: 22396071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.